{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T08:04:26Z","timestamp":1780473866033,"version":"3.54.1"},"reference-count":57,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,1]],"date-time":"2015-01-01T00:00:00Z","timestamp":1420070400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100001422","name":"American Society of Hematology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001422","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2015,1]]},"DOI":"10.1016\/j.thromres.2014.11.011","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T08:29:52Z","timestamp":1416212992000},"page":"102-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Circulating microparticles in patients with antiphospholipid antibodies: Characterization and associations"],"prefix":"10.1016","volume":"135","author":[{"given":"Shruti","family":"Chaturvedi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3016-4471","authenticated-orcid":false,"given":"Erin","family":"Cockrell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo","family":"Espinola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Hsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Fulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suman","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7340-475X","authenticated-orcid":false,"given":"Keith R.","family":"McCrae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2014.11.011_bb0005","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood-2006-04-001206","article-title":"Current concepts on the pathogenesis of the antiphospholipid syndrome","volume":"109","author":"Giannakopoulos","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.011_bb0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1146\/annurev.med.54.101601.152412","article-title":"The antiphospholipid syndrome","volume":"54","author":"Rand","year":"2003","journal-title":"Ann Rev Med"},{"key":"10.1016\/j.thromres.2014.11.011_bb0015","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/S0889-8588(05)70048-4","article-title":"Lupus anticoagulants and antiphospholipid antibodies","volume":"12","author":"Thiagarajan","year":"1998","journal-title":"Hematol Oncol Clin North Am"},{"key":"10.1016\/j.thromres.2014.11.011_bb0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0028-1082267","article-title":"Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms","volume":"34","author":"Pierangeli","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0025","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.011_bb0030","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1055\/s-0038-1646476","article-title":"Lupus anticoagulant IgG's (LA) are not directed to phospholipids only, but to a complex of lipid-bound human prothrombin","volume":"66","author":"Bevers","year":"1991","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0035","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0140-6736(90)91697-9","article-title":"Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease","volume":"335","author":"Matsuura","year":"1990","journal-title":"Lancet"},{"key":"10.1016\/j.thromres.2014.11.011_bb0040","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood-2010-08-300715","article-title":"{beta}2 glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model","volume":"24","author":"Arad","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.011_bb0045","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0050","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1006\/jaut.2000.0407","article-title":"Antiphospholipid antibodies and the protein C pathway","volume":"15","author":"Esmon","year":"2000","journal-title":"J Autoimmun"},{"key":"10.1016\/j.thromres.2014.11.011_bb0055","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1177\/0961203309360841","article-title":"Antiphospholipid antibodies and the protein C pathway","volume":"19","author":"Urbanus","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2014.11.011_bb0060","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1097\/MBC.0b013e32830f1b85","article-title":"Correlation between the potency of a beta2-glycoprotein I-dependent lupus anticoagulant and the level of resistance to activated protein C","volume":"19","author":"de","year":"2008","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.thromres.2014.11.011_bb0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1161\/hh0102.102795","article-title":"Molecular pathogenesis of the antiphospholipid syndrome","volume":"90","author":"Rand","year":"2002","journal-title":"Circ Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0070","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0002-9440(10)63479-7","article-title":"Human monoclonal antiphospholipid antibodies disrupt the annexin A5 anticoagulant crystal shield on phospholipid bilayers: evidence from atomic force microscopy and functional assay","volume":"163","author":"Rand","year":"2003","journal-title":"Am J Pathol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0075","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1172\/JCI118276","article-title":"Activation of cultured vascular endothelial cells by antiphospholipid antibodies","volume":"96","author":"Simantov","year":"1995","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.11.011_bb0080","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/art.1780400322","article-title":"Endothelial cells as targets for antiphospholipid antibodies. Human polyclonal and monoclonal anti-beta 2-glycoprotein I antibodies react in vitro with endothelial cells through adherent beta 2-glycoprotein I and induce endothelial activation","volume":"40","author":"Del Papa","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.11.011_bb0085","series-title":"Activation of endothelial cells by b2GPI\/anti-b2GPI antibodies is mediated by annexin II cross-linking, and may involve TLR4","first-page":"83a","author":"Zhang","year":"2004"},{"key":"10.1016\/j.thromres.2014.11.011_bb0090","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1002\/art.22802","article-title":"Anti-b2-Glycoprotein I antibodies induce monocyte release of tumor necrosis factor a and tissue factor by signal transduction pathways involving lipid rafts","volume":"56","author":"Sorice","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.11.011_bb0095","doi-asserted-by":"crossref","first-page":"6622","DOI":"10.4049\/jimmunol.0902765","article-title":"Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways","volume":"184","author":"Lambrianides","year":"2010","journal-title":"J Immunol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0100","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/art.21968","article-title":"Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib-IX-V","volume":"54","author":"Shi","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.11.011_bb0105","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1538-7836.2007.02310.x","article-title":"Platelet adhesion to dimeric beta-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibalpha and apolipoprotein E receptor 2'","volume":"5","author":"Pennings","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0110","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.20434","article-title":"Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin","volume":"50","author":"Vega-Ostertag","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.thromres.2014.11.011_bb0115","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1046\/j.1538-7836.2003.00119.x","article-title":"E-Selectin mediates pathogenic effects of antiphospholipid antibodies","volume":"1","author":"Espinola","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0120","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2004-05-1708","article-title":"Annexin II mediates endothelial cell activation by antiphospholipid\/anti-\u00df2-glycoprotein I antibodies","volume":"105","author":"Zhang","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.011_bb0125","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0002-9378(12)90915-1","article-title":"Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis","volume":"168","author":"Branch","year":"1993","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0130","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1111\/j.1365-2141.1991.tb08087.x","article-title":"Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies","volume":"79","author":"McCrae","year":"1991","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0135","first-page":"247","article-title":"Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus","volume":"74","author":"Vismara","year":"1988","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0140","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MED.0b013e32835057e9","article-title":"Microvesicles: potential markers and mediators of endothelial dysfunction","volume":"19","author":"Liu","year":"2012","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"10.1016\/j.thromres.2014.11.011_bb0145","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1042\/CS20120309","article-title":"Microparticles: biomarkers and beyond","volume":"124","author":"Burger","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.thromres.2014.11.011_bb0150","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.jash.2012.06.003","article-title":"Microparticles in cardiovascular disease pathophysiology and outcomes","volume":"6","author":"Viera","year":"2012","journal-title":"J Am Soc Hypertens"},{"key":"10.1016\/j.thromres.2014.11.011_bb0155","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1160\/TH10-02-0111","article-title":"Endothelial-derived microparticles: Biological conveyors at the crossroad of inflammation, thrombosis and angiogenesis","volume":"104","author":"Leroyer","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0160","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.thromres.2011.08.020","article-title":"Circulating microparticles and risk of venous thromboembolism","volume":"129","author":"Bucciarelli","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0165","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.thromres.2008.09.005","article-title":"Circulating procoagulant microparticles in patients with venous thromboembolism","volume":"123","author":"Ay","year":"2009","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0170","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1586\/ehm.12.74","article-title":"Microvesicles as risk markers for venous thrombosis","volume":"6","author":"Rautou","year":"2013","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0175","doi-asserted-by":"crossref","first-page":"R156","DOI":"10.1186\/ar2833","article-title":"Increased levels of circulating microparticles in primary Sjogren's syndrome, systemic lupus erythematosus and rheumatoid arthritis and relation with disease activity","volume":"11","author":"Sellam","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.thromres.2014.11.011_bb0180","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1160\/TH05-05-0310","article-title":"Circulating platelet-derived microparticles in systemic lupus erythematosus. Association with increased thrombin generation and procoagulant state","volume":"95","author":"Pereira","year":"2006","journal-title":"Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1016\/j.thromres.2014.11.011_bb0185","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1016\/S0049-3848(10)70022-0","article-title":"Predictive value of tissue factor bearing microparticles in cancer associated thrombosis","volume":"125","author":"Zwicker","year":"2010","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0190","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1111\/bjh.12163","article-title":"Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study)","volume":"160","author":"Zwicker","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0195","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1111\/j.1538-7836.2008.03156.x","article-title":"Plasma tissue factor may be predictive of venous thromboembolism in pancreatic cancer","volume":"6","author":"Khorana","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0200","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1172\/JCI4985","article-title":"In vitro generation of endothelial microparticles and possible prothrombotic activity in patients with the lupus anticoagulant","volume":"104","author":"Combes","year":"1999","journal-title":"J Clin Invest"},{"key":"10.1016\/j.thromres.2014.11.011_bb0205","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1161\/CIRCRESAHA.110.233056","article-title":"Microparticles in hemostasis and thrombosis","volume":"108","author":"Owens","year":"2011","journal-title":"Circ Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0210","doi-asserted-by":"crossref","first-page":"3809","DOI":"10.1016\/S0021-9258(19)39666-8","article-title":"Complement proteins C5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex","volume":"265","author":"Hamilton","year":"1990","journal-title":"J Biol Chem"},{"key":"10.1016\/j.thromres.2014.11.011_bb0215","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1182\/blood-2011-01-330878","article-title":"Monocytic microparticles activate endothelial cells in an IL-1beta-dependent manner","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.thromres.2014.11.011_bb0220","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.thromres.2011.06.004","article-title":"Pre-analytical and analytical variables affecting the measurement of plasma-derived microparticle tissue factor activity","volume":"129","author":"Lee","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0225","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1160\/TH03-07-0487","article-title":"Endothelial microparticles: a potential contribution to the thrombotic complications of the antiphospholipid syndrome","volume":"91","author":"Dignat-George","year":"2004","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0230","first-page":"37","article-title":"Relationship between anti-phospholipid and anti-endothelial cell antibodies: further characterization of the reactivity on resting and cytokine-activated endothelial cells","volume":"10","author":"Del Papa","year":"1992","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.thromres.2014.11.011_bb0235","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1160\/TH12-03-0212","article-title":"Platelet and endothelial activation in catastrophic and quiescent antiphospholipid syndrome","volume":"109","author":"Bontadi","year":"2013","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0240","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1177\/0961203312437809","article-title":"Studies of microparticles in patients with the antiphospholipid syndrome (APS)","volume":"21","author":"Vikerfors","year":"2012","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2014.11.011_bb0245","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.thromres.2007.04.014","article-title":"Platelet activation rather than endothelial injury identifies risk of thrombosis in subjects positive for antiphospholipid antibodies","volume":"121","author":"Jy","year":"2007","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0250","first-page":"10","article-title":"Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus","author":"Perez-Sanchez","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.thromres.2014.11.011_bb0255","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1111\/j.1538-7836.2005.01485.x","article-title":"Lupus anticoagulants and the risk of a first episode of deep venous thrombosis","volume":"3","author":"De Groot","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0260","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1111\/j.1538-7836.2009.03588.x","article-title":"The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study","volume":"7","author":"de Laat","year":"2009","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0265","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1055\/s-0038-1650355","article-title":"Autoantibodies to phospholipid binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies","volume":"75","author":"Pengo","year":"1996","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.thromres.2014.11.011_bb0270","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1177\/096120339200100204","article-title":"A phospholipid-b2-glycoprotein complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection","volume":"1","author":"Hunt","year":"1992","journal-title":"Lupus"},{"key":"10.1016\/j.thromres.2014.11.011_bb0275","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/s11239-013-1000-2","article-title":"Platelet-derived microparticle count and surface molecule expression differ between subjects with and without type 2 diabetes, independently of obesity status","volume":"37","author":"Zhang","year":"2014","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.thromres.2014.11.011_bb0280","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.thromres.2013.05.009","article-title":"Platelet tissue factor: to be or not to be","volume":"132","author":"Mackman","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.thromres.2014.11.011_bb0285","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.thromres.2013.11.027","article-title":"Plasma microparticle tissue factor activity in patients with antiphospholipid antibodies with and without clinical complications","volume":"133","author":"Willemze","year":"2014","journal-title":"Thromb Res"}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384814006203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:37:28Z","timestamp":1758735448000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384814006203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["S0049384814006203"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.011","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Circulating microparticles in patients with antiphospholipid antibodies: Characterization and associations","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2014.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}